Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Oncology

Principles and considerations for Tumor Mutational Burden (TMB) testing

sponsored by Illumina

The identification of biomarkers for the safe and effective use of targeted therapies is emerging as a key part of a cancer patient’s journey. With an increasing number of targeted therapies available, oncologists need comprehensive genomic tools to identify which drugs should be given to a specific patient.

In this webinar, Albrecht Stenzinger will discuss the principles of using next generation sequencing (NGS) to identify the number of genetic alterations in a tumor (called tumor mutational burden or TMB). As an early adopter for using TMB in translational cancer research, Dr. Stenzinger brings valuable insights and considerations for laboratories interested in implementing TMB measurement using NGS.

Wednesday 5 December 2018 at 17.00 CEST

Register Free Here

Learning Objectives of Webinar

  • Gain understanding of the value of Tumor Mutational Burden (TMB) intailoring precision medicine.
  • Learn about key requirements for a robust NGS panel to measure TMB.
  • Hear first-hand insights from a clinical researcher using genomics in translational cancer research

Speaker

Albrecht Stenzinger, M.D.
Head, Center for Molecular Pathology
(CMP)
Head, Section for Biomarker Development
and Molecular Diagnostics
Institute of Pathology Heidelberg (IPH), University Hospital Heidelberg

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Subspecialties Oncology
Invitae microsatellite instability detection

| Contributed by Invitae

Superior Determination of HPV using RNAscope™ In Situ Hybridization

| Contributed by Bio-Techne

Biomarker Optimization on LabSat® Research

| Contributed by Lunaphore Technologies

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register